immatics is a biopharmaceutical company dedicated to the development of innovative cancer immunotherapeutics.
immatics' proprietary basis for the identification of tumor-associated peptides (TUMAPs) enables the development of novel anti-cancer vaccines. immatics has completed a clinical Phase I trial for its first multi-TUMAP product candidate IMA901 treating renal cell carcinoma (RCC) with encouraging results regarding safety and immune responses in connection with clinical responses. immatics was founded in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen (Hans-Georg Rammensee).
To read more, download the complete "COMPANY FACT SHEET"
